{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T21:08:26Z","timestamp":1767474506168},"reference-count":37,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Exp Hematopathol","JCEH"],"published-print":{"date-parts":[[2011]]},"DOI":"10.3960\/jslrt.51.21","type":"journal-article","created":{"date-parts":[[2011,5,31]],"date-time":"2011-05-31T05:57:56Z","timestamp":1306821476000},"page":"21-28","source":"Crossref","is-referenced-by-count":64,"title":["The Diagnosis and Management of Extranodal NK\/T-Cell Lymphoma, Nasal-Type and Aggressive NK-Cell Leukemia"],"prefix":"10.3960","volume":"51","author":[{"given":"Yok-Lam","family":"Kwong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Spits H, Lanier LL, Phillips JH: Development of human T and natural killer cells. Blood 85:2654-2670, 1995","DOI":"10.1182\/blood.V85.10.2654.bloodjournal85102654"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Kwong YL: Natural killer-cell malignancies: diagnosis and treatment. Leukemia 19:2186-2194, 2005","DOI":"10.1038\/sj.leu.2403955"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Oshimi K: Progress in understanding and managing natural killer-cell malignancies. Br J Haematol 139:532-544, 2007","DOI":"10.1111\/j.1365-2141.2007.06835.x"},{"key":"4","unstructured":"4 Batsakis JG, Luna MA: Midfacial necrotizing lesions. Semin Diagn Pathol 4:90-116, 1987"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, <I>et al <\/I>: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994","DOI":"10.1182\/blood.V84.5.1361.bloodjournal8451361"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Wong KF, Chan JK, Ng CS, Lee KC, Tsang WY, <I>et al <\/I>: CD56 (NKH1)-positive hematolymphoid malignancies: an aggressive neoplasm featuring frequent cutaneous\/mucosal involvement, cytoplasmic azurophilic granules, and angiocentricity. Hum Pathol 23:798-804, 1992","DOI":"10.1016\/0046-8177(92)90350-C"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Chan JK, Tsang WY, Ng CS: Clarification of CD3 immunoreactivity in nasal T\/natural killer cell lymphomas: the neoplastic cells are often CD3&#949;<SUP>+<\/SUP>. Blood 87:839-841, 1996","DOI":"10.1182\/blood.V87.2.839.bloodjournal872839"},{"key":"8","unstructured":"8 Chan JKC, Quintanilla-Martinez L, Ferry JA, Peh S-C: Extranodal NK\/T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, <I>et al<\/I>. (eds): World Health Organization Classification of Tumours, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed, International Agency for Research on Cancer (IARC), Lyon, pp. 285-288, 2008"},{"key":"9","unstructured":"9 Chan JK, Yip TT, Tsang WY, Ng CS, Lau WH, <I>et al<\/I>. : Detection of Epstein-Barr viral RNA in malignant lymphomas of the upper aerodigestive tract. Am J Surg Pathol 18:938-946, 1994"},{"key":"10","doi-asserted-by":"crossref","unstructured":"11 Cohen JI, Kimura H, Nakamura S, Ko YH, Jaffe ES: Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. Ann Oncol 20:1472-1482, 2009","DOI":"10.1093\/annonc\/mdp064"},{"key":"11","unstructured":"12 Chan JK, Jaffe ES, Ralfkiaer E, Ko YH: Aggressive NK-cell leukaemia. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, <I>et al<\/I>. (eds): World Health Organization Classification of Tumours, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed, International Agency for Research on Cancer (IARC), Lyon, pp. 276-277, 2008"},{"key":"12","unstructured":"13 Cheung MM, Chan JK, Lau WH, Foo W, Chan PT, <I>et al<\/I>. : Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 16:70-77, 1998"},{"key":"13","unstructured":"14 Chan JK, Sin VC, Wong KF, Ng CS, Tsang WY, <I>et al<\/I>. : Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 89:4501-4513, 1997"},{"key":"14","unstructured":"15 Suzuki R, Suzumiya J, Nakamura S, Aoki S, Notoya A, <I>et al<\/I>. : NK-cell Tumor Study Group. Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia 18:763-770, 2004"},{"key":"15","doi-asserted-by":"crossref","unstructured":"16 Wong KF, Chan JK, Cheung MM, So JC: Bone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon. Am J Clin Pathol 115:266-270, 2001","DOI":"10.1309\/E5PR-6A9R-Q02N-8QVW"},{"key":"16","unstructured":"17 Lee J, Suh C, Huh J, Jun HJ, Kim K, <I>et al<\/I>. : Effect of positive bone marrow EBV <I>in situ<\/I> hybridization in staging and survival of localized extranodal natural killer\/T-cell lymphoma, nasal-type. Clin Cancer Res 13:3250-3254, 2007"},{"key":"17","doi-asserted-by":"crossref","unstructured":"18 Khong PL, Pang CB, Liang R, Kwong YL, Au WY: Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann Hematol 87:613-621, 2008","DOI":"10.1007\/s00277-008-0494-8"},{"key":"18","doi-asserted-by":"crossref","unstructured":"19 Au WY, Pang A, Choy C, Chim CS, Kwong YL: Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV positive lymphomas in immunocompetent patients. Blood 104:243-249, 2004","DOI":"10.1182\/blood-2003-12-4197"},{"key":"19","unstructured":"20 Chim CS, Ma SY, Au WY, Choy C, Lie AK, <I>et al<\/I>. : Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 103:216-221, 2004"},{"key":"20","unstructured":"21 Lee J, Suh C, Park YH, Ko YH, Bang SM, <I>et al<\/I>. : Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 24:612-618, 2006"},{"key":"21","unstructured":"22 Suzuki R, Suzumiya J, Yamaguchi M, Nakamura S, Kameoka J, <I>et al<\/I>. : NK-cell Tumor Study Group. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol 21:1032-1040, 2010"},{"key":"22","unstructured":"23 Kwong YL, Anderson BO, Advani R, Kim WS, Levine AM, <I>et al<\/I>. : Management of T-cell and natural-killer-cell neoplasms in Asia: Consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 10:1093-1101, 2009"},{"key":"23","unstructured":"24 Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, <I>et al<\/I>. : Phase I\/II study of concurrent chemoradiotherapy for localized nasal natural killer\/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 27:5594-5600, 2009"},{"key":"24","unstructured":"25 Kim SJ, Kim K, Kim BS, Kim CY, Suh C, <I>et al<\/I>. : Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK\/T-cell lymphoma: Consortium for improving survival of lymphoma study. J Clin Oncol 27:6027-6032, 2009"},{"key":"25","doi-asserted-by":"crossref","unstructured":"26 Kwong YL: High-dose chemotherapy and hematopoietic SCT in the management of natural killer-cell malignancies. Bone Marrow Transplant 44:709-714, 2009","DOI":"10.1038\/bmt.2009.239"},{"key":"26","unstructured":"27 Ishida F, Nishina S, Asano N, Sasaki S, Sekiguchi N, <I>et al<\/I>. : Late relapse of extranodal natural killer\/T cell lymphoma, nasal type, after more than ten years. Leuk Lymphoma 51:171-173, 2010"},{"key":"27","unstructured":"28 Au WY, Kim SJ, Yiu HH, Ngan RK, Loong F, <I>et al<\/I>. : Clinicopathological features and outcome of late relapses of natural killer cell lymphomas 10-29 years after initial remission. Am J Hematol 85:362-363, 2010"},{"key":"28","unstructured":"29 Yamaguchi M, Suzuki R, Kwong YL, Kim WS, Hasegawa Y, <I>et al<\/I>. : Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)\/T-cell lymphoma and leukemia. Cancer Sci 99:1016-1020, 2008"},{"key":"29","unstructured":"30 Kwong YL, Yamaguchi M, Maeda Y, Hashimoto C, Kim WS, <I>et al<\/I>. : NK-cell Tumor Study Group. Phase II study of SMILE chemothearpy for newly-diagnosed stage IV, relapsed or refractory extranodal NK\/T-cell lymphoma, nasal type: NKTSG study. Haematologica 95:0299, 2010 (<I>Abstract<\/I>)"},{"key":"30","unstructured":"31 Jaccard A, Petit B, Girault S, Suarez F, Gressin R, <I>et al<\/I>. : L-asparaginase-based treatment of 15 western patients with extranodal NK\/T-cell lymphoma and leukemia and a review of the literature. Ann Oncol 20:110-116, 2009"},{"key":"31","unstructured":"32 Yong W, Zheng W, Zhu J, Zhang Y, Wang X, <I>et al<\/I>. : L-asparaginase in the treatment of refractory and relapsed extranodal NK\/T-cell lymphoma, nasal type. Ann Hematol 88:647-652, 2009"},{"key":"32","unstructured":"33 Kim BS, Kim DW, Im SA, Kim CW, Kim TY, <I>et al<\/I>. : Effective second-line chemotherapy for extranodal NK\/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone. Ann Oncol 20:121-128, 2009"},{"key":"33","unstructured":"34 Ito T, Makishima H, Nakazawa H, Kobayashi H, Shimodaira S, <I>et al<\/I>. : Promising approach for aggressive NK cell leukaemia with allogeneic haematopoietic cell transplantation. Eur J Haematol 81:107-111, 2008"},{"key":"34","unstructured":"35 Lee J, Au WY, Park MJ, Suzumiya J, Nakamura S, <I>et al<\/I>. : Autologous hematopoietic stem cell transplantation in extranodal natural killer\/T cell lymphoma: A multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant 14:1356-1364, 2008"},{"key":"35","unstructured":"36 Murashige N, Kami M, Kishi Y, Kim SW, Takeuchi M, <I>et al<\/I>. : Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol 130:561-567, 2005"},{"key":"36","unstructured":"37 Kako S, Izutsu K, Oshima K, Sato H, Kanda Y, <I>et al<\/I>. : Regression of the tumor after withdrawal of cyclosporine in relapsed extranodal natural killer\/T cell lymphoma following allogeneic hematopoietic stem cell transplantation. Am J Hematol 82:937-939, 2007"},{"key":"37","unstructured":"38 Sato E, Ohga S, Kuroda H, Yoshiba F, Nishimura M, <I>et al<\/I>. : Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T\/natural killer-cell lymphoproliferative disease in Japan. Am J Hematol 83:721-727, 2008"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T19:46:00Z","timestamp":1621539960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/51\/1\/51_1_21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.51.21","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011]]}}}